Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia
- Priority review accelerates FDA evaluation and may shorten the path to potential approval
- Regulatory progress could strengthen BridgeBio’s pediatric achondroplasia franchise and commercial outlook
- Full development and review details appear in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted oral infigratinib NDA with Priority Review, setting a February 4, 2027 PDUFA target date
- Potential first approved oral achondroplasia therapy, supporting BridgeBio’s planned U.S. launch upon approval
- PROPEL 3 achieved +2.10 cm/year AHV treatment effect versus placebo, p<0.0001
- Statistically significant improvements in body proportionality and arm span, strengthening differentiation beyond height
- Planned EMA marketing application in fourth quarter 2026 expands potential international commercialization path
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.